Cranbury, NJ, January 4, 2006 - Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-active pharmacological chaperones for the treatment of human genetic diseases, today announced that the company will present at the 24th Annual JPMorgan Healthcare Conference. This will be the company's first public presentation since a new management team was put into place with the appointment of John F. Crowley as chairman and CEO in January 2005. The presentation will take place at 3 p.m. PT on Monday, January 9, 2006, at the Westin St. Francis Hotel in San Francisco.
Amicus Therapeutics is a clinical stage company pioneering a paradigm-shifting approach to treating a wide range of genetic diseases in which crucial proteins are misfolded. Amicus develops pharmacological chaperones - orally-active, small molecule drugs - that selectively bind to the affected protein, restoring shape, proper trafficking, and biological function. This approach offers the potential to significantly improve treatment options for patients.
In September, Amicus announced the closing of a $55 million Series C financing. The company's lead compound Amigal (migalastat hydrochloride) is in Phase ll clinical trials for Fabry disease and the company plans to initiate clinical trials of a new product for the treatment of Gaucher disease in the first half of 2006. In addition, the company has a growing pipeline of other products for a range of genetic diseases.